E. Zakiev, F. Rached, M. Lhomme, M. Darabi-amin, M. Ponnaiah et al., Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency, Journal of Clinical Lipidology, vol.13, issue.3, pp.468-480.e8, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02166947

V. Sukhorukov, I. Gudelj, M. Pu?i?-bakovi?, E. Zakiev, A. Orekhov et al., Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1864, issue.5, pp.643-653, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02135945

L. Lagrost, D. Masson, and J. Chapman, Lipoprotéines et métabolisme lipidique, pp.59-74, 2003.

R. J. Havel, J. P. Kane-;-c, and . Scriver, Introduction : Structure and Metabolism of plasma lipoproteins., in The metabolic and molecular bases of inherited disease, pp.1841-1853, 2001.

K. Berg, . New, S. Type, and . System, A NEW SERUM TYPE SYSTEM IN MAN-THE Lp SYSTEM, Acta Pathologica Microbiologica Scandinavica, vol.59, issue.3, pp.369-382, 2009.

W. H. Tang and S. L. Hazen, Microbiome, trimethylamine N-oxide, and cardiometabolic disease, Translational Research, vol.179, pp.108-115, 2017.

A. F. Sigurdsson, VLDL -The Role of Triglyceride-Rich Lipoproteins and Remnant Cholesterol

J. P. Segrest, Structure of apolipoprotein B-100 in low density lipoproteins, J Lipid Res, vol.42, issue.9, pp.1346-67, 2001.

M. Dashti, W. Kulik, F. Hoek, E. C. Veerman, M. P. Peppelenbosch et al., A Phospholipidomic Analysis of All Defined Human Plasma Lipoproteins, Scientific Reports, vol.1, issue.1, p.139, 2011.

M. Dashty, M. Motazacker, J. Levels, M. D. Vries, M. Mahmoudi et al., Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism, Thrombosis and Haemostasis, vol.111, issue.03, pp.518-530, 2014.

F. Ga, High-Density Lipoproteins, Biochemistry of Lipids, Lipoproteins and Membranes, pp.437-457, 2016.

B. F. Asztalos, M. Tani, and B. M. Ishida, The Complexity of High-Density Lipoproteins, The HDL Handbook, pp.37-64, 2014.

R. S. Rosenson, H. B. Brewer, M. J. Chapman, S. Fazio, M. M. Hussain et al., HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events, Clinical Chemistry, vol.57, issue.3, pp.392-410, 2011.

L. J. Anderson, J. K. Boyles, and M. M. Hussain, A rapid method for staining large chylomicrons, J Lipid Res, vol.30, issue.11, pp.1819-1843, 1989.

D. Gantz, Size and shape determination of fixed chylomicrons and emulsions with fluid or solid surfaces by three-dimensional analysis of shadows, J Lipid Res, vol.31, issue.1, pp.163-71, 1990.

N. O. Davidson, M. E. Kollmer, and R. M. Glickman, Apolipoprotein B synthesis in rat small intestine: regulation by dietary triglyceride and biliary lipid, J Lipid Res, vol.27, issue.1, pp.30-39, 1986.

P. H. Green and J. W. Riley, Lipid Absorption and Intestinal Lipoprotein Formation, Australian and New Zealand Journal of Medicine, vol.11, issue.1, pp.84-90, 1981.

D. B. Zilversmit, Formation and transport of chylomicrons, Fed Proc, vol.26, issue.6, pp.1599-605, 1967.

D. B. Zilversmit, The composition and structure of lymph chylomicrons in dog, rat, and man., Journal of Clinical Investigation, vol.44, issue.10, pp.1610-1622, 1965.

K. W. Miller and D. M. Small, Surface-to-core and interparticle equilibrium distributions of triglyceride-rich lipoprotein lipids, J Biol Chem, vol.258, issue.22, pp.13772-84, 1983.

J. H. Brussaard, G. Dallinga-thie, P. H. Groot, and M. B. Katan, Effects of amount and type of dietary fat on serum lipids, lipoproteins and apolipoproteins in man, Atherosclerosis, vol.36, issue.4, pp.515-527, 1980.

R. Hay and G. S. Getz, Translation in vivo and in vitro of proteins resembling apoproteins of rat plasma very low density lipoprotein, J Lipid Res, vol.20, issue.3, pp.334-382, 1979.

M. D. Robertson, Mobilisation of enterocyte fat stores by oral glucose in humans, Gut, vol.52, issue.6, pp.834-839, 2003.

C. Xiao, J. Hsieh, K. Adeli, and G. F. Lewis, Gut-liver interaction in triglyceride-rich lipoprotein metabolism, American Journal of Physiology-Endocrinology and Metabolism, vol.301, issue.3, pp.E429-E446, 2011.

G. F. Gibbons, D. Wiggins, A. Brown, and A. Hebbachi, Synthesis and function of hepatic very-low-density lipoprotein, Biochemical Society Transactions, vol.32, issue.1, pp.59-64, 2004.

J. P. Kane, T. Sata, R. L. Hamilton, and R. J. Havel, Apoprotein composition of very low density lipoproteins of human serum., Journal of Clinical Investigation, vol.56, issue.6, pp.1622-1634, 1975.

G. S. Shelness and J. A. Sellers, Very-low-density lipoprotein assembly and secretion, Current Opinion in Lipidology, vol.12, issue.2, pp.151-157, 2001.

J. H. Rapp, A. Lespine, R. L. Hamilton, N. Colyvas, A. H. Chaumeton et al., Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque., Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, vol.14, issue.11, pp.1767-1774, 1994.

G. H. Tomkin and D. Owens, Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis, Diabetes/Metabolism Research and Reviews, vol.17, issue.1, pp.27-43, 2001.

D. F. Vine, D. R. Glimm, and S. D. Proctor, Intestinal lipid transport and chylomicron production: Possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome, Atherosclerosis Supplements, vol.9, issue.2, pp.69-76, 2008.

P. W. Wilson, R. B. D?agostino, D. Levy, A. M. Belanger, H. Silbershatz et al., Prediction of Coronary Heart Disease Using Risk Factor Categories, Circulation, vol.97, issue.18, pp.1837-1847, 1998.

A. R. Sharrett, C. M. Ballantyne, S. A. Coady, G. Heiss, P. D. Sorlie et al., Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions, Circulation, vol.104, issue.10, pp.1108-1113, 2001.

C. J. Willer, S. Sanna, A. U. Jackson, A. Scuteri, L. L. Bonnycastle et al., Newly identified loci that influence lipid concentrations and risk of coronary artery disease, Nature Genetics, vol.40, issue.2, pp.161-169, 2008.

N. O. Stitziel, Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease, New England Journal of Medicine, vol.371, issue.22, pp.2072-2082, 2014.

P. Linsel-nitschke, A. Götz, J. Erdmann, I. Braenne, P. Braund et al., Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease?A Mendelian Randomisation Study, PLoS ONE, vol.3, issue.8, p.e2986, 2008.

S. Stender, R. Frikke-schmidt, B. G. Nordestgaard, and A. Tybjærg-hansen, The ABCG5/8 Cholesterol Transporter and Myocardial Infarction Versus Gallstone Disease, Journal of the American College of Cardiology, vol.63, issue.20, pp.2121-2128, 2014.

J. Crosby, Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease, New England Journal of Medicine, vol.371, issue.1, pp.22-31, 2014.

B. A. Ference, Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis, J Am Coll Cardiol, vol.60, issue.25, pp.2631-2640, 2012.

A. M. Navar-boggan, E. D. Peterson, R. B. D?agostino, B. Neely, A. D. Sniderman et al., Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease, Circulation, vol.131, issue.5, pp.451-458, 2015.

B. Mihaylova, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, The Lancet, vol.380, issue.9841, pp.581-590, 2012.

D. P. Barr, E. M. Russ, and H. A. Eder, Protein-lipid relationships in human plasma, The American Journal of Medicine, vol.11, issue.4, pp.480-493, 1951.

E. Nikkila, Studies on the lipid-protein relationship in normal and pathological sera and the effect of heparin on serum lipoproteins, Scand J Clin Lab Invest, vol.8, issue.5, pp.9-100, 1953.

J. A. Glomset, Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins, J Lipid Res, vol.7, issue.5, pp.638-686, 1966.

G. J. Miller and N. E. Miller, PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE, The Lancet, vol.305, issue.7897, pp.16-19, 1975.

D. J. Gordon, J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli et al., High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies., Circulation, vol.79, issue.1, pp.8-15, 1989.

D. R. Jacobs, I. L. Mebane, S. I. Bangdiwala, M. H. Criqui, and H. A. Tyroler, HIGH DENSITY LIPOPROTEIN CHOLESTEROL AS A PREDICTOR OF CARDIOVASCULAR DISEASE MORTALITY IN MEN AND WOMEN: THE FOLLOW-UP STUDY OF THE LIPID RESEARCH CLINICS PREVALENCE STUDY, American Journal of Epidemiology, vol.131, issue.1, pp.32-47, 1990.

P. P. Toth, P. J. Barter, R. S. Rosenson, W. E. Boden, M. J. Chapman et al., High-density lipoproteins: A consensus statement from the National Lipid Association, Journal of Clinical Lipidology, vol.7, issue.5, pp.484-525, 2013.

J. W. Gofman, W. Young, and R. Tandy, Ischemic Heart Disease, Atherosclerosis, and Longevity, Circulation, vol.34, issue.4, pp.679-697, 1966.

G. G. Rhoads, C. L. Gulbrandsen, and A. Kagan, Serum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men, New England Journal of Medicine, vol.294, issue.6, pp.293-298, 1976.

N. E. Miller, The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study, Lancet, vol.1, issue.8019, pp.965-973, 1977.

G. Assmann, H. Schulte, A. Von-eckardstein, and Y. Huang, High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis, vol.124, pp.S11-S20, 1996.

U. Goldbourt, S. Yaari, and J. H. Medalie, Isolated Low HDL Cholesterol As a Risk Factor for Coronary Heart Disease Mortality, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.17, issue.1, pp.107-113, 1997.

G. Heiss, G. Schonfeld, J. L. Johnson, S. Heyden, C. G. Hames et al., Black-white differences in plasma levels of apolipoproteins: The Evans County Heart Study, American Heart Journal, vol.108, issue.3, pp.807-814, 1984.

S. M. Haffner, M. P. Stern, H. P. Hazuda, M. Rosenthal, and J. A. Knapp, THE ROLE OF BEHAVIORAL VARIABLES AND FAT PATTERNING IN EXPLAINING ETHNIC DIFFERENCES IN SERUM LIPIDS AND LIPOPROTEINS1, American Journal of Epidemiology, vol.123, issue.5, pp.830-839, 1986.

N. Saha, Serum high density lipoprotein cholesterol, apolipoprotein A-I, A-II and B levels in Singapore ethnic groups, Atherosclerosis, vol.68, issue.1-2, pp.117-121, 1987.

G. Heiss, The epidemiology of plasma high-density lipoprotein cholesterol levels. The Lipid Research Clinics Program Prevalence Study. Summary. Circulation, vol.62, pp.116-152, 1980.

J. C. Seidell, M. Cigolini, J. Charzewska, B. Ellsinger, and G. D. Biase, Fat Distribution in European Women: A Comparison of Anthropometric Measurements in Relation to Cardiovascular Risk Factors, International Journal of Epidemiology, vol.19, issue.2, pp.303-308, 1990.

R. D. Santos, E. J. Schaefer, B. F. Asztalos, E. Polisecki, J. Wang et al., Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency, Journal of Lipid Research, vol.49, issue.2, pp.349-357, 2007.

J. M. Chehade, M. Gladysz, and A. D. Mooradian, Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management, Drugs, vol.73, issue.4, pp.327-339, 2013.

C. Morgantini, D. Meriwether, S. Baldi, E. Venturi, S. Pinnola et al., HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease, Nutrition, Metabolism and Cardiovascular Diseases, vol.24, issue.6, pp.594-599, 2014.

H. R. Superko, L. Pendyala, P. T. Williams, K. M. Momary, S. B. King et al., High-density lipoprotein subclasses and their relationship to cardiovascular disease, Journal of Clinical Lipidology, vol.6, issue.6, pp.496-523, 2012.

A. Pirillo, G. D. Norata, and A. L. Catapano, High-Density Lipoprotein Subfractions - What the Clinicians Need to Know, Cardiology, vol.124, issue.2, pp.116-125, 2013.

F. H. Rached, M. J. Chapman, and A. Kontush, HDL particle subpopulations: Focus on biological function, BioFactors, vol.41, issue.2, pp.67-77, 2015.

J. L. Brown and . Hypercholesterolemia, The Online Metabolic and Molecular Bases of Inherited Disease, pp.2863-913, 2001.

J. D. Brunzell and D. S. , Lipoprotein Lipase Deficiency, Familial, The Metabolic & Molecular Bases of Inherited Disease, pp.2789-816

B. G. Nordestgaard, S. Stender, and K. Kjeldsen, Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall., Arteriosclerosis: An Official Journal of the American Heart Association, Inc., vol.8, issue.4, pp.421-428, 1988.

B. G. Nordestgaard, S. Stender, and K. Kjeldsen, Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall., Arteriosclerosis: An Official Journal of the American Heart Association, Inc., vol.8, issue.4, pp.421-428, 1988.

M. Shaikh, R. Wootton, B. G. Nordestgaard, P. Baskerville, J. S. Lumley et al., Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans., Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, vol.11, issue.3, pp.569-577, 1991.

B. G. Nordestgaard, A. Tybjaerg-hansen, and B. Lewis, Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants., Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, vol.12, issue.1, pp.6-18, 1992.

B. G. Nordestgaard, R. Wootton, and B. Lewis, Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In Vivo, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.15, issue.4, pp.534-542, 1995.

B. G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjærg-hansen, Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women, JAMA, vol.298, issue.3, p.299, 2007.

S. Bansal, J. E. Buring, N. Rifai, S. Mora, F. M. Sacks et al., Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women, JAMA, vol.298, issue.3, p.309, 2007.

J. J. Freiberg, Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population, JAMA, vol.300, issue.18, p.2142, 2008.

E. Di-angelantonio, Major lipids, apolipoproteins, and risk of vascular disease, Jama, vol.302, issue.18, pp.1993-2000, 2009.

A. Varbo, M. Benn, A. Tybjærg-hansen, A. B. Jørgensen, R. Frikke-schmidt et al., Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease, Journal of the American College of Cardiology, vol.61, issue.4, pp.427-436, 2013.

M. J. Chapman, H. N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén et al., 32 TRIGLYCERIDE-RICH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE: EVIDENCE AND GUIDANCE FOR MANAGEMENT, Atherosclerosis Supplements, vol.12, issue.1, p.7, 2011.

A. Varbo, M. Benn, and B. G. Nordestgaard, Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment, Pharmacology & Therapeutics, vol.141, issue.3, pp.358-367, 2014.

W. S. Davidson and T. B. Thompson, The Structure of Apolipoprotein A-I in High Density Lipoproteins, Journal of Biological Chemistry, vol.282, issue.31, pp.22249-22253, 2007.

A. Wlodawer, J. P. Segrest, B. H. Chung, R. Chiovetti, and J. N. Weinstein, High-density lipoprotein recombinants: evidence for a bicycle tire micelle structure obtained by neutron scattering and electron microscopy, FEBS Letters, vol.104, issue.2, pp.231-235, 1979.

J. P. Segrest, M. K. Jones, A. E. Klon, C. J. Sheldahl, M. Hellinger et al., A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein, Journal of Biological Chemistry, vol.274, issue.45, pp.31755-31758, 1999.

R. A. Silva, R. Huang, J. Morris, J. Fang, E. O. Gracheva et al., Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes, Proceedings of the National Academy of Sciences, vol.105, issue.34, pp.12176-12181, 2008.

V. Gogonea, Structural Insights into High Density Lipoprotein: Old Models and New Facts, Frontiers in Pharmacology, vol.6, issue.6, 2016.

K. Rye, C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter, The metabolism and anti-atherogenic properties of HDL, Journal of Lipid Research, vol.50, issue.Supplement, pp.S195-S200, 2008.

E. J. Schaefer, R. D. Santos, and B. F. Asztalos, Marked HDL deficiency and premature coronary heart disease, Current Opinion in Lipidology, vol.21, issue.4, pp.289-297, 2010.

L. Camont, M. Lhomme, F. Rached, W. Le-goff, A. Nègre-salvayre et al., Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.33, issue.12, pp.2715-2723, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02352432

P. Duriez and J. C. Fruchart, High-density lipoprotein subclasses and apolipoprotein A-I, Clinica Chimica Acta, vol.286, issue.1-2, pp.97-114, 1999.

N. E. Miller, HDL metabolism and its role in lipid transport, European Heart Journal, vol.11, issue.suppl H, pp.1-3, 1990.

M. C. Cheung, Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins, J Lipid Res, vol.27, issue.11, pp.1135-1179, 1986.

S. Lund-katz, High density lipoprotein structure, Front Biosci, vol.8, pp.1044-54, 2003.

T. Vaisar, S. Pennathur, P. S. Green, S. A. Gharib, A. N. Hoofnagle et al., Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL, Journal of Clinical Investigation, vol.117, issue.3, pp.746-756, 2007.

A. D. Tselepis and M. John-chapman, Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase, Atherosclerosis Supplements, vol.3, issue.4, pp.57-68, 2002.

L. Li, J. Han, Z. Wang, J. Liu, J. Wei et al., Mass Spectrometry Methodology in Lipid Analysis, International Journal of Molecular Sciences, vol.15, issue.6, pp.10492-10507, 2014.

A. Scanu and J. L. Granda, Effects of Ultracentrifugation on the Human Serum High-Density (1.063 < ? < 1.21 g/ml) Lipoprotein*, Biochemistry, vol.5, issue.2, pp.446-455, 1966.

P. Edman and G. Begg, A Protein Sequenator, European Journal of Biochemistry, vol.1, pp.80-91, 1967.

W. S. Davidson, R. Silva, S. Chantepie, W. Lagor, M. Chapman et al., Abstract: 80 PROTEOMIC ANALYSIS OF DEFINED HDL SUBPOPULATIONS REVEALS PARTICLE-SPECIFIC PROTEIN CLUSTERS: RELEVANCE TO ANTIOXIDATIVE FUNCTION, Atherosclerosis Supplements, vol.10, issue.2, p.e219, 2009.

J. Mcclements, The rheology of emulsion-based food products, Texture in Food, vol.5, pp.3-35, 2003.

L. Camont, M. Lhomme, F. Rached, W. Le-goff, A. Nègre-salvayre et al., Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.33, issue.12, pp.2715-2723, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02352432

A. Kontush, M. Lhomme, and M. J. Chapman, Unraveling the complexities of the HDL lipidome, Journal of Lipid Research, vol.54, issue.11, pp.2950-2963, 2013.

S. Lucke and B. Levkau, Endothelial Functions of Sphingosine-1-phosphate, Cellular Physiology and Biochemistry, vol.26, issue.1, pp.87-96, 2010.

P. M. Christensen, M. H. Bosteen, S. Hajny, L. B. Nielsen, and C. Christoffersen, Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes, Scientific Reports, vol.7, issue.1, p.14983, 2017.

A. Kontush, M. Lindahl, M. Lhomme, L. Calabresi, M. J. Chapman et al., Structure of HDL: Particle Subclasses and Molecular Components, High Density Lipoproteins, vol.224, pp.3-51, 2014.

F. Rached, M. Lhomme, L. Camont, F. Gomes, C. Dauteuille et al., Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1851, issue.9, pp.1254-1261, 2015.

G. K. Marathe, C. Pandit, C. L. Lakshmikanth, V. H. Chaithra, S. P. Jacob et al., To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase, Journal of Lipid Research, vol.55, issue.9, pp.1847-1854, 2014.

H. Xu, N. Valenzuela, S. Fai, D. Figeys, and S. A. Bennett, Targeted lipidomics - advances in profiling lysophosphocholine and platelet-activating factor second messengers, FEBS Journal, vol.280, issue.22, pp.5652-5667, 2013.

J. W. Zmijewski, Cell signalling by oxidized lipids and the role of reactive oxygen species in the endothelium, Biochem Soc Trans, vol.33, pp.1385-1394, 2005.

M. L. Litvack and N. Palaniyar, Review: Soluble innate immune pattern-recognition proteins for clearing dying cells and cellular components: implications on exacerbating or resolving inflammation, Innate Immunity, vol.16, issue.3, pp.191-200, 2010.

H. K. Lim, Y. Choi, W. Park, T. Lee, S. H. Ryu et al., Phosphatidic Acid Regulates Systemic Inflammatory Responses by Modulating the Akt-Mammalian Target of Rapamycin-p70 S6 Kinase 1 Pathway, Journal of Biological Chemistry, vol.278, issue.46, pp.45117-45127, 2003.

C. Delon, M. Manifava, E. Wood, D. Thompson, S. Krugmann et al., Sphingosine Kinase 1 Is an Intracellular Effector of Phosphatidic Acid, Journal of Biological Chemistry, vol.279, issue.43, pp.44763-44774, 2004.

D. R. Green, Apoptosis and Sphingomyelin Hydrolysis, Journal of Cell Biology, vol.150, issue.1, pp.F5-F8, 2000.

P. Wiesner, K. Leidl, A. Boettcher, G. Schmitz, and G. Liebisch, Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry, Journal of Lipid Research, vol.50, issue.3, pp.574-585, 2008.

J. Huang, H. Lee, A. M. Zivkovic, J. T. Smilowitz, N. Rivera et al., Glycomic Analysis of High Density Lipoprotein Shows a Highly Sialylated Particle, Journal of Proteome Research, vol.13, issue.2, pp.681-691, 2014.

S. Krishnan, J. Huang, H. Lee, A. Guerrero, L. Berglund et al., Combined High-Density Lipoprotein Proteomic and Glycomic Profiles in Patients at Risk for Coronary Artery Disease, Journal of Proteome Research, vol.14, issue.12, pp.5109-5118, 2015.

S. Krishnan, M. Shimoda, R. Sacchi, M. J. Kailemia, G. Luxardi et al., HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes, Scientific Reports, vol.7, issue.1, p.43728, 2017.

P. Májek, K. Pecankova, M. Maly, M. Oravec, T. Riedel et al., N-Glycosylation of apolipoprotein A1 in cardiovascular diseases, Translational Research, vol.165, issue.2, pp.360-362, 2015.

M. J. Kailemia, W. Wei, K. Nguyen, E. Beals, L. Sawrey-kubicek et al., Targeted Measurements of O- and N-Glycopeptides Show That Proteins in High Density Lipoprotein Particles Are Enriched with Specific Glycosylation Compared to Plasma, Journal of Proteome Research, vol.17, issue.2, pp.834-845, 2017.

J. S. Millar, The sialylation of plasma lipoproteins, Atherosclerosis, vol.154, issue.1, pp.1-13, 2001.

L. Camont, M. J. Chapman, and A. Kontush, Biological activities of HDL subpopulations and their relevance to cardiovascular disease, Trends in Molecular Medicine, vol.17, issue.10, pp.594-603, 2011.

S. Goulinet and M. J. Chapman, Plasma LDL and HDL Subspecies Are Heterogenous in Particle Content of Tocopherols and Oxygenated and Hydrocarbon Carotenoids, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.17, issue.4, pp.786-796, 1997.

B. F. Asztalos, P. S. Roheim, R. L. Milani, M. Lefevre, J. R. Mcnamara et al., Distribution of ApoA-I?Containing HDL Subpopulations in Patients With Coronary Heart Disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.12, pp.2670-2676, 2000.

A. Kontush and M. J. Chapman, Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis, Pharmacological Reviews, vol.58, issue.3, pp.342-374, 2006.

E. M. Tsompanidi, M. S. Brinkmeier, E. H. Fotiadou, S. M. Giakoumi, and K. E. Kypreos, HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis, Atherosclerosis, vol.208, issue.1, pp.3-9, 2010.

G. F. Lewis and D. J. Rader, New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport, Circulation Research, vol.96, issue.12, pp.1221-1232, 2005.

G. H. Rothblat and M. C. Phillips, High-density lipoprotein heterogeneity and function in reverse cholesterol transport, Current Opinion in Lipidology, vol.21, issue.3, pp.229-238, 2010.

L. Yvan-charvet, N. Wang, and A. R. Tall, Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune Responses, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.2, pp.139-143, 2010.

D. J. Rader, Molecular regulation of HDL metabolism and function: implications for novel therapies, Journal of Clinical Investigation, vol.116, issue.12, pp.3090-3100, 2006.

C. G. Santos-gallego, B. Ibanez, and J. J. Badimon, HDL-cholesterol: Is it really good?, Biochemical Pharmacology, vol.76, issue.4, pp.443-452, 2008.

M. J. Chapman, W. Le-goff, M. Guerin, and A. Kontush, Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors, European Heart Journal, vol.31, issue.2, pp.149-164, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00581336

L. K. Curtiss, D. T. Valenta, N. J. Hime, and K. Rye, What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport?, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.26, issue.1, pp.12-19, 2006.

C. Röhrl, T. A. Pagler, W. Strobl, A. Ellinger, J. Neumüller et al., Characterization of endocytic compartments after holo-high density lipoprotein particle uptake in HepG2 cells, Histochemistry and Cell Biology, vol.133, issue.3, pp.261-272, 2009.

C. Röhrl and H. Stangl, HDL endocytosis and resecretion, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1831, issue.11, pp.1626-1633, 2013.

A. Kontush and M. J. Chapman, Antiatherogenic small, dense HDL?guardian angel of the arterial wall?, Nature Clinical Practice Cardiovascular Medicine, vol.3, issue.3, pp.144-153, 2006.

S. Ganjali, G. M. Dallinga-thie, L. E. Simental-mendía, M. Banach, M. Pirro et al., HDL functionality in type 1 diabetes, Atherosclerosis, vol.267, pp.99-109, 2017.

C. Besler, T. F. Lüscher, and U. Landmesser, Molecular mechanisms of vascular effects of High?density lipoprotein: alterations in cardiovascular disease, EMBO Molecular Medicine, vol.4, issue.4, pp.251-268, 2012.

J. A. Glomset and J. L. Wright, Some properties of a cholesterol esterifying enzyme in human plasma, Biochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects, vol.89, issue.2, pp.266-276, 1964.

A. R. Tall, Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins, Journal of Internal Medicine, vol.263, issue.3, pp.256-273, 2008.

M. P. Adorni, F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader et al., The roles of different pathways in the release of cholesterol from macrophages, Journal of Lipid Research, vol.48, issue.11, pp.2453-2462, 2007.

M. R. Hayden, S. M. Clee, A. Brooks-wilson, J. Genest, A. Attie et al., Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency, Current Opinion in Lipidology, vol.11, issue.2, pp.117-122, 2000.

J. F. Oram, Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1, Trends in Molecular Medicine, vol.8, issue.4, pp.168-173, 2002.

J. J. Repa and D. J. Mangelsdorf, The liver X receptor gene team: Potential new players in atherosclerosis, Nature Medicine, vol.8, issue.11, pp.1243-1248, 2002.

N. Wang, D. Lan, W. Chen, F. Matsuura, and A. R. Tall, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proceedings of the National Academy of Sciences, vol.101, issue.26, pp.9774-9779, 2004.

M. A. Kennedy, G. C. Barrera, K. Nakamura, Á. Baldán, P. Tarr et al., ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation, Cell Metabolism, vol.1, issue.2, pp.121-131, 2005.

G. H. Rothblat, Cell cholesterol efflux: integration of old and new observations provides new insights, J Lipid Res, vol.40, issue.5, pp.781-96, 1999.

S. D. Covey, M. Krieger, W. Wang, M. Penman, and B. L. Trigatti, Scavenger Receptor Class B Type I?Mediated Protection Against Atherosclerosis in LDL Receptor?Negative Mice Involves Its Expression in Bone Marrow?Derived Cells, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.9, pp.1589-1594, 2003.

W. Zhang, P. G. Yancey, Y. R. Su, V. R. Babaev, Y. Zhang et al., Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E?Deficient Mice, Circulation, vol.108, issue.18, pp.2258-2263, 2003.

Y. Zhang, I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat et al., Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo, Circulation, vol.108, issue.6, pp.661-663, 2003.

A. Von-eckardstein, J. R. Nofer, and G. Assmann, High Density Lipoproteins and Arteriosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.1, pp.13-27, 2001.

M. Westerterp, M. Van-eck, W. De-haan, E. H. Offerman, T. J. Van-berkel et al., Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol efflux from macrophages, Atherosclerosis, vol.195, issue.1, pp.e9-e16, 2007.

N. Rotllan, V. Ribas, L. Calpe-berdiel, J. M. Marti?n-campos, F. Blanco-vaca et al., Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.25, issue.9, pp.1896-1896, 2005.

P. G. Yancey, M. De-la-llera-moya, S. Swarnakar, P. Monzo, S. M. Klein et al., High Density Lipoprotein Phospholipid Composition Is a Major Determinant of the Bi-directional Flux and Net Movement of Cellular Free Cholesterol Mediated by Scavenger Receptor BI, Journal of Biological Chemistry, vol.275, issue.47, pp.36596-36604, 2000.

W. S. Davidson, K. L. Gillotte, S. Lund-katz, W. J. Johnson, G. H. Rothblat et al., The Effect of High Density Lipoprotein Phospholipid Acyl Chain Composition on the Efflux of Cellular Free Cholesterol, Journal of Biological Chemistry, vol.270, issue.11, pp.5882-5890, 1995.

J. Nofer and G. Assmann, Atheroprotective Effects of High-Density Lipoprotein-Associated Lysosphingolipids, Trends in Cardiovascular Medicine, vol.15, issue.7, pp.265-271, 2005.

L. Zhou, C. Li, L. Gao, and A. Wang, High-density lipoprotein synthesis and metabolism (Review), Molecular Medicine Reports, vol.12, issue.3, pp.4015-4021, 2015.

G. Assmann and A. M. Gotto, HDL Cholesterol and Protective Factors in Atherosclerosis, Circulation, vol.109, issue.23_suppl_1, p.III-8-III-14, 2004.

S. J. Nicholls, G. J. Dusting, B. Cutri, S. Bao, G. R. Drummond et al., Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits, Circulation, vol.111, issue.12, pp.1543-1550, 2005.

B. J. Van-lenten, The Role of High-Density Lipoproteins in Oxidation and Inflammation, Trends in Cardiovascular Medicine, vol.11, issue.3-4, pp.155-161, 2001.

M. Navab, G. M. Ananthramaiah, S. T. Reddy, B. J. Van-lenten, B. J. Ansell et al., Thematic review series: The Pathogenesis of AtherosclerosisThe oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL, Journal of Lipid Research, vol.45, issue.6, pp.993-1007, 2004.

A. Kontush and M. J. Chapman, Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities, Current Opinion in Lipidology, vol.21, issue.4, pp.312-318, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00614294

A. Zerrad-saadi, P. Therond, S. Chantepie, M. Couturier, K. Rye et al., HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.12, pp.2169-2175, 2009.

S. Chantepie, E. Malle, W. Sattler, M. J. Chapman, and A. Kontush, Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl, Archives of Biochemistry and Biophysics, vol.487, issue.1, pp.28-35, 2009.

M. Navab, J. A. Berliner, G. Subbanagounder, S. Hama, A. J. Lusis et al., HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.4, pp.481-488, 2001.

E. Boisfer, D. Stengel, D. Pastier, E. Dugué, P. M. Laplaud et al., Human apolipoprotein A-II expression in mice decreases antioxydant properties of HDL, Atherosclerosis Supplements, vol.2, issue.2, p.72, 2001.

V. Ribas, J. L. Sa?nchez-quesada, R. Anto?n, M. Camacho, J. Julve et al., Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties, Circulation Research, vol.95, issue.8, pp.789-797, 2004.

M. A. Ostos, M. Conconi, L. Vergnes, N. Baroukh, J. Ribalta et al., Antioxidative and Antiatherosclerotic Effects of Human Apolipoprotein A-IV in Apolipoprotein E?Deficient Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.6, pp.1023-1028, 2001.

J. Davignon, Apolipoprotein E and Atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.25, issue.2, pp.267-269, 2005.

M. Navab, S. Hama-levy, B. J. Van-lenten, G. C. Fonarow, C. J. Cardinez et al., Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio., Journal of Clinical Investigation, vol.99, issue.8, pp.2005-2019, 1997.

I. P. Trougakos, M. Lourda, G. Agiostratidou, D. Kletsas, and E. S. Gonos, Differential effects of clusterin/apolipoprotein J on cellular growth and survival, Free Radical Biology and Medicine, vol.38, issue.4, pp.436-449, 2005.

B. Dahlbäck and L. B. Nielsen, Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation?, Cellular and Molecular Life Sciences, vol.66, issue.4, pp.559-564, 2009.

A. Kontush, S. Chantepie, and M. J. Chapman, Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.10, pp.1881-1888, 2003.

L. Calabresi, M. Gomaraschi, and G. Franceschini, Endothelial Protection by High-Density Lipoproteins, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.10, pp.1724-1731, 2003.

C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto et al., Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease, Journal of Clinical Investigation, vol.121, issue.7, pp.2693-2708, 2011.

J. T. Kuvin, M. E. Rämet, A. R. Patel, N. G. Pandian, M. E. Mendelsohn et al., A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression, American Heart Journal, vol.144, issue.1, pp.165-172, 2002.

C. Mineo, I. S. Yuhanna, M. J. Quon, and P. W. Shaul, High Density Lipoprotein-induced Endothelial Nitric-oxide Synthase Activation Is Mediated by Akt and MAP Kinases, Journal of Biological Chemistry, vol.278, issue.11, pp.9142-9149, 2003.

J. R. Nofer, M. Van-der-giet, M. Tölle, I. Wolinska, K. Von-wnuck-lipinski et al., HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3, Journal of Clinical Investigation, vol.113, issue.4, pp.569-581, 2004.

B. G. Drew, N. H. Fidge, G. Gallon-beaumier, B. E. Kemp, and B. A. Kingwell, High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation, Proceedings of the National Academy of Sciences, vol.101, issue.18, pp.6999-7004, 2004.

A. C. Calkin, B. G. Drew, A. Ono, S. J. Duffy, M. V. Gordon et al., Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux, Circulation, vol.120, issue.21, pp.2095-2104, 2009.

J. R. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann et al., HDL and arteriosclerosis: beyond reverse cholesterol transport, Atherosclerosis, vol.161, issue.1, pp.1-16, 2002.

Y. Li, J. B. Dong, and M. P. Wu, Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice, European Journal of Pharmacology, vol.590, issue.1-3, pp.417-422, 2008.

K. M. Argraves, A. A. Sethi, P. J. Gazzolo, B. A. Wilkerson, A. T. Remaley et al., S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease, Lipids in Health and Disease, vol.10, issue.1, p.70, 2011.

M. F. Brodde, S. J. Korporaal, G. Herminghaus, M. Fobker, T. J. Van-berkel et al., Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI, Atherosclerosis, vol.215, issue.2, pp.374-382, 2011.

M. Darabi and A. Kontush, Phosphatidylserine in atherosclerosis, Current Opinion in Lipidology, vol.27, issue.4, pp.414-420, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01382705

S. Fichtlscherer, A. M. Zeiher, and S. Dimmeler, Circulating MicroRNAs, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.31, issue.11, pp.2383-2390, 2011.

S. De-rosa, S. Fichtlscherer, R. Lehmann, B. Assmus, S. Dimmeler et al., Transcoronary Concentration Gradients of Circulating MicroRNAs, Circulation, vol.124, issue.18, pp.1936-1944, 2011.

J. Wagner, M. Riwanto, C. Besler, A. Knau, S. Fichtlscherer et al., Characterization of Levels and Cellular Transfer of Circulating Lipoprotein-Bound MicroRNAs, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.33, issue.6, pp.1392-1400, 2013.

M. Mackness, P. Durrington, and B. Mackness, Paraoxonase 1 activity, concentration and genotype in cardiovascular disease, Current Opinion in Lipidology, vol.15, issue.4, pp.399-404, 2004.

M. Aviram and J. Vaya, Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion, Current Opinion in Lipidology, vol.24, issue.4, pp.339-344, 2013.

E. J. Schaefer, P. Anthanont, and B. F. Asztalos, High-density lipoprotein metabolism, composition, function, and deficiency, Current Opinion in Lipidology, vol.25, issue.3, pp.194-199, 2014.

A. V. Khera, M. Cuchel, and M. De-la-llera-moya, Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis, Journal of Vascular Surgery, vol.54, issue.1, pp.280-281, 2011.

X. M. Li, W. H. Tang, M. K. Mosior, Y. Huang, Y. Wu et al., Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.33, issue.7, pp.1696-1705, 2013.

A. Kontush and M. J. Chapman, Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis, Pharmacological Reviews, vol.58, issue.3, pp.342-374, 2006.

A. Von-eckardstein, Differential diagnosis of familial high density lipoprotein deficiency syndromes, Atherosclerosis, vol.186, issue.2, pp.231-239, 2006.

G. Chiesa and C. R. Sirtori, Apolipoprotein A-IMilano: current perspectives, Current Opinion in Lipidology, vol.14, issue.2, pp.159-163, 2003.

J. F. Oram and A. M. Vaughan, ATP-Binding Cassette Cholesterol Transporters and Cardiovascular Disease, Circulation Research, vol.99, issue.10, pp.1031-1043, 2006.

A. Ossoli, S. Simonelli, C. Vitali, G. Franceschini, and L. Calabresi, Role of LCAT in Atherosclerosis, Journal of Atherosclerosis and Thrombosis, vol.23, issue.2, pp.119-127, 2016.

F. Oldoni, D. Baldassarre, S. Castelnuovo, A. Ossoli, M. Amato et al., Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis, Circulation, vol.138, issue.10, pp.1000-1007, 2018.

D. Weissglas-volkov and P. Pajukanta, Genetic causes of high and low serum HDL-cholesterol, Journal of Lipid Research, vol.51, issue.8, pp.2032-2057, 2010.

B. Lamarche, S. Rashid, and G. F. Lewis, HDL metabolism in hypertriglyceridemic states: an overview, Clinica Chimica Acta, vol.286, issue.1-2, pp.145-161, 1999.

J. F. Thompson, L. S. Wood, E. H. Pickering, B. Dechairo, and C. L. Hyde, High-density genotyping and functional SNP localization in the CETP gene, Journal of Lipid Research, vol.48, issue.2, pp.434-443, 2006.

W. Khovidhunkit, M. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser et al., Thematic review series: The Pathogenesis of Atherosclerosis.Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host, Journal of Lipid Research, vol.45, issue.7, pp.1169-1196, 2004.

A. Rohatgi, A. Khera, J. D. Berry, E. G. Givens, C. R. Ayers et al., HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events, New England Journal of Medicine, vol.371, issue.25, pp.2383-2393, 2014.

A. Kontush and M. J. Chapman, Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities, Current Opinion in Lipidology, vol.21, issue.4, pp.312-318, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00614294

A. Kontush and M. J. Chapman, High-Density Lipoproteins, High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02965526

S. M. Gordon, J. H. Chung, M. P. Playford, A. K. Dey, D. Sviridov et al., High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography, Atherosclerosis, vol.278, pp.278-285, 2018.

B. J. Van-lenten, S. Y. Hama, F. C. De-beer, D. M. Stafforini, T. M. Mcintyre et al., Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures., Journal of Clinical Investigation, vol.96, issue.6, pp.2758-2767, 1995.

M. Dobiasova, Lecithin: cholesterol acyltransferase and the regulation of endogenous cholesterol transport, Adv Lipid Res, vol.20, pp.107-94, 1983.

L. M. Harada, M. D. Carvalho, M. Passarelli, and E. C. Quintão, Lipoprotein desialylation simultaneously enhances the cell cholesterol uptake and impairs the reverse cholesterol transport system: in vitro evidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages, Atherosclerosis, vol.139, issue.1, pp.65-75, 1998.

P. Marmillot, M. N. Rao, Q. Liu, and M. R. Lakshman, Desialylation of human apolipoprotein E decreases its binding to human high-density lipoprotein and its ability to deliver esterified cholesterol to the liver, Metabolism, vol.48, issue.9, pp.1184-1192, 1999.

O. V. Savinova, K. Fillaus, L. Jing, W. S. Harris, and G. C. Shearer, Reduced Apolipoprotein Glycosylation in Patients with the Metabolic Syndrome, PLoS ONE, vol.9, issue.8, p.e104833, 2014.

P. J. Barter, M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein et al., Effects of Torcetrapib in Patients at High Risk for Coronary Events, New England Journal of Medicine, vol.357, issue.21, pp.2109-2122, 2007.

M. A. Connelly, T. J. Parry, E. C. Giardino, Z. Huang, W. Cheung et al., Torcetrapib Produces Endothelial Dysfunction Independent of Cholesteryl Ester Transfer Protein Inhibition, Journal of Cardiovascular Pharmacology, vol.55, issue.5, pp.459-468, 2010.

G. G. Schwartz, A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter et al., Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome, New England Journal of Medicine, vol.367, issue.22, pp.2089-2099, 2012.

A. M. Lincoff, S. J. Nicholls, J. S. Riesmeyer, P. J. Barter, H. B. Brewer et al., Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease, Journal of Vascular Surgery, vol.66, issue.4, p.1302, 2017.

H. T. Group, Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease, New England Journal of Medicine, vol.377, issue.13, pp.1217-1227, 2017.

J. Armitage, M. V. Holmes, and D. Preiss, Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events, Journal of the American College of Cardiology, vol.73, issue.4, pp.477-487, 2019.

S. E. Nissen, T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper et al., Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes, JAMA, vol.290, issue.17, p.2292, 2003.

J. A. Reijers, D. G. Kallend, K. E. Malone, J. W. Jukema, P. L. Wijngaard et al., MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216, Cardiovascular Drugs and Therapy, vol.31, issue.4, pp.381-389, 2017.

H. J. Kempen, D. B. Schranz, B. F. Asztalos, J. Otvos, E. Jeyarajah et al., Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size, Journal of Lipids, vol.2014, pp.1-8, 2014.

S. J. Nicholls, R. Puri, C. M. Ballantyne, J. W. Jukema, J. J. Kastelein et al., Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial, JAMA Cardiology, vol.3, issue.9, p.806, 2018.

J. C. Tardif, Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.297, issue.15, p.1675, 2007.

C. Michael-gibson, S. Korjian, P. Tricoci, Y. Daaboul, M. Yee et al., Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction, Circulation, vol.134, issue.24, pp.1918-1930, 2016.

S. A. Didichenko, A. V. Navdaev, A. M. Cukier, A. Gille, P. Schuetz et al., Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112, Circulation Research, vol.119, issue.6, pp.751-763, 2016.

R. S. Kootte, L. P. Smits, F. M. Van-der-valk, J. Dasseux, C. H. Keyserling et al., Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA, Journal of Lipid Research, vol.56, issue.3, pp.703-712, 2015.

Y. Kataoka, J. Andrews, M. Duong, T. Nguyen, N. Schwarz et al., Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden, Cardiovascular Diagnosis and Therapy, vol.7, issue.3, pp.252-263, 2017.

J. C. Tardif, Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.297, issue.15, p.1675, 2007.

S. J. Nicholls, J. Andrews, J. J. Kastelein, B. Merkely, S. E. Nissen et al., Effect of Serial Infusions of CER-001, a Pre-? High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial, JAMA Cardiology, vol.3, issue.9, p.815, 2018.

R. Waksman, R. Torguson, K. M. Kent, A. D. Pichard, W. O. Suddath et al., A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome, Journal of the American College of Cardiology, vol.55, issue.24, pp.2727-2735, 2010.

M. Navab, I. Shechter, G. M. Anantharamaiah, S. T. Reddy, B. J. Van-lenten et al., Structure and Function of HDL Mimetics, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.2, pp.164-168, 2010.

L. T. Bloedon, R. Dunbar, D. Duffy, P. Pinell-salles, R. Norris et al., Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients, Journal of Lipid Research, vol.49, issue.6, pp.1344-1352, 2008.

M. Ditiatkovski, J. Palsson, J. Chin-dusting, A. T. Remaley, and D. Sviridov, Apolipoprotein A-I Mimetic Peptides, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.37, issue.7, pp.1301-1306, 2017.

R. D. Shamburek, R. Bakker-arkema, A. M. Shamburek, L. A. Freeman, M. J. Amar et al., Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study, Circulation Research, vol.118, issue.1, pp.73-82, 2016.

M. J. Graham, R. G. Lee, T. A. Bell, W. Fu, A. E. Mullick et al., Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans, Circulation Research, vol.112, issue.11, pp.1479-1490, 2013.

X. H. Yang, S. Lee, Y. Choi, V. J. Alexander, A. Digenio et al., Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results, Journal of Lipid Research, vol.57, issue.4, pp.706-713, 2016.

M. J. Chapman, J. S. Redfern, M. E. Mcgovern, and P. Giral, Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk, Pharmacology & Therapeutics, vol.126, issue.3, pp.314-345, 2010.

J. Millan, X. Pintó, A. Brea, M. Blasco, A. Hernández-mijares et al., Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration, Clínica e Investigación en Arteriosclerosis (English Edition), vol.30, issue.1, pp.30-35, 2018.

E. Araki, S. Yamashita, H. Arai, K. Yokote, J. Satoh et al., Effects of Pemafibrate, a Novel Selective PPAR? Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial, Diabetes Care, vol.41, issue.3, pp.538-546, 2018.

L. J. Scott, Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency, Drugs, vol.75, issue.2, pp.175-182, 2015.

W. E. Boden, Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy, New England Journal of Medicine, vol.365, issue.24, pp.2255-2267, 2011.

H. T. Group, Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients, New England Journal of Medicine, vol.371, issue.3, pp.203-212, 2014.

S. Schandelmaier, M. Briel, R. Saccilotto, K. K. Olu, A. Arpagaus et al., Niacin for primary and secondary prevention of cardiovascular events, Cochrane Database of Systematic Reviews, issue.6, p.2017, 2017.

D. Keene, C. Price, M. J. Shun-shin, and D. P. Francis, Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients, BMJ, vol.349, issue.jul18 2, pp.g4379-g4379, 2014.

S. J. Nicholls, A. Gordon, J. Johansson, K. Wolski, C. M. Ballantyne et al., Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease, Journal of the American College of Cardiology, vol.57, issue.9, pp.1111-1119, 2011.

S. J. Nicholls, R. Puri, K. Wolski, C. M. Ballantyne, P. J. Barter et al., Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial, American Journal of Cardiovascular Drugs, vol.16, issue.1, pp.55-65, 2015.

D. Shishikura, Y. Kataoka, S. Honda, K. Takata, S. W. Kim et al., The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial, American Journal of Cardiovascular Drugs, vol.19, issue.1, pp.49-57, 2018.

S. J. Nicholls, K. K. Ray, J. O. Johansson, A. Gordon, M. Sweeney et al., Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease, American Journal of Cardiovascular Drugs, vol.18, issue.2, pp.109-115, 2017.

T. Nomiyama and D. Bruemmer, Liver X receptors as therapeutic targets in metabolism and atherosclerosis, Current Atherosclerosis Reports, vol.10, issue.1, pp.88-95, 2008.

A. Katz, C. Udata, E. Ott, L. Hickey, M. E. Burczynski et al., Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants, The Journal of Clinical Pharmacology, vol.49, issue.6, pp.643-649, 2009.

S. Yonezawa, M. Abe, Y. Kawasaki, Y. Natori, and A. Sugiyama, Each liver X receptor (LXR) type has a different purpose in different situations, Biochemical and Biophysical Research Communications, vol.508, issue.1, pp.92-96, 2019.

S. H. Najafi-shoushtari, F. Kristo, Y. Li, T. Shioda, D. E. Cohen et al., MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis, Science, vol.328, issue.5985, pp.1566-1569, 2010.

K. J. Rayner, Y. Suarez, A. Davalos, S. Parathath, M. L. Fitzgerald et al., MiR-33 Contributes to the Regulation of Cholesterol Homeostasis, Science, vol.328, issue.5985, pp.1570-1573, 2010.

M. R. Diffenderfer and E. J. Schaefer, The composition and metabolism of large and small LDL, Current Opinion in Lipidology, vol.25, issue.3, pp.221-226, 2014.

P. Wiesner, K. Leidl, A. Boettcher, G. Schmitz, and G. Liebisch, Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry, Journal of Lipid Research, vol.50, issue.3, pp.574-585, 2008.

M. Vauhkonen, J. Viitala, J. Parkkinen, and H. Rauvala, High-mannose structure of apolipoprotein-B from low-density lipoproteins of human plasma, European Journal of Biochemistry, vol.152, issue.1, pp.43-50, 1985.

V. V. Tertov, Carbohydrate composition of protein and lipid components in sialic acid-rich and -poor low density lipoproteins from subjects with and without coronary artery disease, J Lipid Res, vol.34, issue.3, pp.365-75, 1993.

N. Swaminathan and F. Aladjem, The monosaccharide composition and sequence of the carbohydrate moiety of human serum low density lipoproteins, Biochemistry, vol.15, issue.7, pp.1516-1522, 1976.

M. Khosravi, R. Hosseini-fard, and M. Najafi, Circulating low density lipoprotein (LDL), Hormone Molecular Biology and Clinical Investigation, vol.35, issue.2, 2018.

C. J. Packard, Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions, J Lipid Res, vol.41, issue.2, pp.305-323, 2000.

C. A. Aguilar-salinas, P. H. Barrett, J. Pulai, X. L. Zhu, and G. Schonfeld, A Familial Combined Hyperlipidemic Kindred With Impaired Apolipoprotein B Catabolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.17, issue.1, pp.72-82, 1997.

H. C. Geiss, S. Bremer, P. H. Barrett, C. Otto, and K. G. Parhofer, In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy, Journal of Lipid Research, vol.45, issue.8, pp.1459-1467, 2004.

C. Zheng, C. Khoo, J. Furtado, and F. M. Sacks, Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype, Circulation, vol.121, issue.15, pp.1722-1734, 2010.

V. E. Bouhairie and A. C. Goldberg, Familial Hypercholesterolemia, Cardiology Clinics, vol.33, issue.2, pp.169-179, 2015.

P. Davidsson, J. Hulthe, B. Fagerberg, B. Olsson, C. Hallberg et al., A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes, Journal of Lipid Research, vol.46, issue.9, pp.1999-2006, 2005.

A. N. Orekhov, Y. Bobryshev, I. Sobenin, A. Melnichenko, and D. Chistiakov, Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease, International Journal of Molecular Sciences, vol.15, issue.7, pp.12807-12841, 2014.

A. Orekhov, Y. Bobryshev, I. Sobenin, A. Melnichenko, and D. Chistiakov, Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease, International Journal of Molecular Sciences, vol.15, issue.7, pp.12807-12841, 2014.

A. N. Orekhov, V. V. Tertov, D. N. Mukhin, and I. A. Mikhailenko, Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: Discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients, Biochemical and Biophysical Research Communications, vol.162, issue.1, pp.206-211, 1989.

I. A. Sobenin, V. V. Tertov, T. Koschinsky, C. E. Bünting, E. S. Slavina et al., Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells, Atherosclerosis, vol.100, issue.1, pp.41-54, 1993.

V. V. Tertov, I. A. Sobenin, A. G. Tonevitsky, A. N. Orekhov, and V. N. Smirnov, Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: Separation from native lipoprotein by affinity chromatography, Biochemical and Biophysical Research Communications, vol.167, issue.3, pp.1122-1127, 1990.

A. N. Orekhov, Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation, J Lipid Res, vol.33, issue.6, pp.805-822, 1992.

V. V. Tertov, I. A. Sobenin, A. N. Orekhov, O. Jaakkola, T. Solakivi et al., Characteristics of low density lipoprotein isolated from circulating immune complexes, Atherosclerosis, vol.122, issue.2, pp.191-199, 1996.

A. N. Orekhov, V. V. Tertov, and D. N. Mukhin, Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency, Atherosclerosis, vol.86, issue.2-3, pp.153-161, 1991.

V. V. Tertov, I. A. Sobenin, Z. A. Gabbasov, E. G. Popov, and A. N. Orekhov, Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins, Biochemical and Biophysical Research Communications, vol.163, issue.1, pp.489-494, 1989.

A. L. Bartlett, T. Grewal, E. De-angelis, S. Myers, and K. K. Stanley, Role of the macrophage galactose lectin in the uptake of desialylated LDL, Atherosclerosis, vol.153, issue.1, pp.219-230, 2000.

J. V. Hunt, M. A. Bottoms, K. Clare, J. T. Skamarauskas, and M. J. Mitchinson, Glucose oxidation and low-density lipoprotein-induced macrophage ceroid accumulation: possible implications for diabetic atherosclerosis, Biochemical Journal, vol.300, issue.1, pp.243-249, 1994.

B. E. Brown, I. Rashid, D. M. Van-reyk, and M. J. Davies, Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages, FEBS Journal, vol.274, issue.6, pp.1530-1541, 2007.

G. M. Chisolm and D. Steinberg, The oxidative modification hypothesis of atherogenesis: an overview, Free Radical Biology and Medicine, vol.28, issue.12, pp.1815-1826, 2000.

A. N. Orekhov, V. V. Tertov, and D. N. Mukhin, Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency, Atherosclerosis, vol.86, issue.2-3, pp.153-161, 1991.

T. Grewal, A. Bartlett, J. W. Burgess, N. H. Packer, and K. K. Stanley, Desialylated LDL uptake in human and mouse macrophages can be mediated by a lectin receptor, Atherosclerosis, vol.121, issue.1, pp.151-163, 1996.

A. Oesterle, U. Laufs, and J. K. Liao, Pleiotropic Effects of Statins on the Cardiovascular System, Circulation Research, vol.120, issue.1, pp.229-243, 2017.

D. R. Mager, Statins, Home Healthcare Now, vol.34, issue.7, pp.388-393, 2016.

A. M. Ferreira and P. Marques-da-silva, Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia, American Journal of Cardiovascular Drugs, vol.17, issue.3, pp.169-181, 2016.

A. Karatasakis, B. A. Danek, J. Karacsonyi, B. V. Rangan, M. K. Roesle et al., Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta?Analysis of 35 Randomized Controlled Trials, Journal of the American Heart Association, vol.6, issue.12, 2017.

F. Rached, R. D. Santos, L. Camont, M. H. Miname, M. Lhomme et al., Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome, Journal of Lipid Research, vol.55, issue.12, pp.2509-2520, 2014.

C. W. Hamm and E. Braunwald, A Classification of Unstable Angina Revisited, Circulation, vol.102, issue.1, pp.118-122, 2000.

S. C. Rumsey, Human plasma LDL cryopreserved with sucrose maintains in vivo kinetics indistinguishable from freshly isolated human LDL in cynomolgus monkeys, J Lipid Res, vol.35, issue.9, pp.1592-1600, 1994.

G. Lefèvre, I. Myara, J. Peynet, R. Couderc, and . Gerbap-section-lipoprotéines, Effect of sucrose/ ? 80°C storage of plasma on between-site values of low-density lipoprotein susceptibility to copper-induced oxidation, Clinica Chimica Acta, vol.258, issue.2, pp.249-255, 1997.

O. Favier, Causes de décès et surmortalité après lymphome de Hodgkin. Analyse des données de huit essais de l?organisation européenne pour la recherche et le traitement du cancer et du groupe d?étude des lymphomes de l?adulte, Revue d'Épidémiologie et de Santé Publique, vol.56, issue.2, pp.129-130, 2008.

M. Guérin, Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, vol.16, pp.763-772, 1996.

M. J. Chapman, A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum, J Lipid Res, vol.22, issue.2, pp.339-58, 1981.

M. J. Chapman, A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum, J Lipid Res, vol.22, issue.2, pp.339-358, 1981.

M. Guerin, P. Egger, W. Le-goff, C. Soudant, R. Dupuis et al., Atorvastatin Reduces Postprandial Accumulation and Cholesteryl Ester Transfer Protein-Mediated Remodeling of Triglyceride-Rich Lipoprotein Subspecies in Type IIB Hyperlipidemia, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.11, pp.4991-5000, 2002.

A. Kontush, E. C. De-faria, S. Chantepie, and M. J. Chapman, Antioxidative Activity of HDL Particle Subspecies Is Impaired in Hyperalphalipoproteinemia: Relevance of Enzymatic and Physicochemical Properties, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.24, issue.3, pp.526-533, 2004.

B. Larijani, D. L. Poccia, and L. C. Dickinson, Phospholipid identification and quantification of membrane vesicle subfractions by 31P?1H two-dimensional nuclear magnetic resonance, Lipids, vol.35, issue.11, pp.1289-1297, 2000.

O. Quehenberger, Lipidomics reveals a remarkable diversity of lipids in human plasma, Journal of Lipid Research, vol.51, issue.11, pp.3299-3305, 2010.

O. Quehenberger and E. A. Dennis, The Human Plasma Lipidome, New England Journal of Medicine, vol.365, issue.19, pp.1812-1823, 2011.

A. Kontush, P. Therond, A. Zerrad, M. Couturier, A. Ne?gre-salvayre et al., Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.27, issue.8, pp.1843-1849, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00409657

I. T. Akmacic, High-throughput glycomics: optimization of sample preparation, Biochemistry (Mosc), vol.80, issue.7, pp.934-976, 2015.

K. R. Reiding, D. Blank, D. M. Kuijper, A. M. Deelder, and M. Wuhrer, High-Throughput Profiling of Protein N-Glycosylation by MALDI-TOF-MS Employing Linkage-Specific Sialic Acid Esterification, Analytical Chemistry, vol.86, issue.12, pp.5784-5793, 2014.

S. Larrede, C. M. Quinn, W. Jessup, E. Frisdal, M. Olivier et al., Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.11, pp.1930-1936, 2009.

N. Fournier, V. Atger, A. Cogny, B. Vedie, P. Giral et al., Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system, Atherosclerosis, vol.157, issue.2, pp.315-323, 2001.

A. Kontush, S. Chantepie, and M. J. Chapman, Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.10, pp.1881-1888, 2003.

E. Nob?court, S. Jacqueminet, B. Hansel, S. Chantepie, A. Grimaldi et al., Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia, Diabetologia, vol.48, issue.3, pp.529-538, 2005.

B. Hansel, A. Kontush, and M. T. Twickler, High-Density Lipoprotein as a Key Component in the Prevention of Premature Atherosclerotic Disease in the Insulin Resistance Syndrome, Seminars in Vascular Medicine, vol.4, issue.2, pp.215-223, 2004.

R. Stocker, Lipoprotein oxidation, Current Opinion in Lipidology, vol.5, issue.6, pp.422-433, 1994.

C. A. Abbott, M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington, Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and Lipoproteins, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.15, issue.11, pp.1812-1818, 1995.

J. Nofer, B. Levkau, I. Wolinska, R. Junker, M. Fobker et al., Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids, Journal of Biological Chemistry, vol.276, issue.37, pp.34480-34485, 2001.

F. Jourdan, L. Cottret, L. Huc, D. Wildridge, R. Scheltema et al., Use of reconstituted metabolic networks to assist in metabolomic data visualization and mining, Metabolomics, vol.6, issue.2, pp.312-321, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02662801

M. Kanehisa, S. Goto, Y. Sato, M. Kawashima, M. Furumichi et al., Data, information, knowledge and principle: back to metabolism in KEGG, Nucleic Acids Research, vol.42, issue.D1, pp.D199-D205, 2013.

J. Xia and D. S. Wishart, Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis, Current Protocols in Bioinformatics, vol.55, issue.1, pp.14.10.1-14.10.91, 2016.

J. J. Goeman, S. A. Van-de-geer, F. De-kort, and H. C. Van-houwelingen, A global test for groups of genes: testing association with a clinical outcome, Bioinformatics, vol.20, issue.1, pp.93-99, 2003.

M. Hummel, R. Meister, and U. Mansmann, GlobalANCOVA: exploration and assessment of gene group effects, Bioinformatics, vol.24, issue.1, pp.78-85, 2007.

A. Kontush and M. J. Chapman, High-density lipoproteins, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02965526

B. Jaspard, Biochemical characterization of pre-beta 1 high-density lipoprotein from human ovarian follicular fluid: evidence for the presence of a lipid core, Biochemistry, vol.35, issue.5, pp.1352-1359, 1996.

Y. Hamon, ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine, Nat Cell Biol, vol.2, issue.7, pp.399-406, 2000.

W. V. Rodrigueza, Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells, J Biol Chem, vol.274, issue.29, pp.20344-50, 1999.

J. H. Jang, Understanding of the roles of phospholipase D and phosphatidic acid through their binding partners, Prog Lipid Res, vol.51, issue.2, pp.71-81, 2012.

W. S. Davidson, R. Silva, S. Chantepie, W. Lagor, M. Chapman et al., Abstract: 80 PROTEOMIC ANALYSIS OF DEFINED HDL SUBPOPULATIONS REVEALS PARTICLE-SPECIFIC PROTEIN CLUSTERS: RELEVANCE TO ANTIOXIDATIVE FUNCTION, Atherosclerosis Supplements, vol.10, issue.2, p.e219, 2009.

G. Wan, S. Zhaorigetu, Z. Liu, R. Kaini, Z. Jiang et al., Apolipoprotein L1, a Novel Bcl-2 Homology Domain 3-only Lipid-binding Protein, Induces Autophagic Cell Death, Journal of Biological Chemistry, vol.283, issue.31, pp.21540-21549, 2008.

P. T. Duong, H. L. Collins, M. Nickel, S. Lund-katz, G. H. Rothblat et al., Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I, Journal of Lipid Research, vol.47, issue.4, pp.832-843, 2006.

E. Favari, L. Calabresi, M. P. Adorni, W. Jessup, S. Simonelli et al., Small Discoidal Pre-?1 HDL Particles Are Efficient Acceptors of Cell Cholesterol via ABCA1 and ABCG1, Biochemistry, vol.48, issue.46, pp.11067-11074, 2009.

X. M. Du, M. Kim, L. Hou, W. Le-goff, M. J. Chapman et al., HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol Export, Circulation Research, vol.116, issue.7, pp.1133-1142, 2015.

J. A. De-souza, C. Vindis, A. Nègre-salvayre, K. Rye, M. Couturier et al., Small, dense HDL3 particles attenuates apoptosis in endothelial cells: Pivotal role of apolipoprotein A-I, Journal of Cellular and Molecular Medicine, vol.14, issue.3, pp.608-628, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02352462

Y. Zhao, D. L. Sparks, and Y. L. Marcel, Effect of the apolipoprotein A-I and surface lipid composition of reconstituted discoidal HDL on cholesterol efflux from cultured fibroblasts, Biochemistry, vol.35, issue.51, pp.16510-16518, 1996.

S. Hara, Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells, Arterioscler Thromb Vasc Biol, vol.17, issue.7, pp.1258-66, 1997.

M. Rosenblat, Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine, Atherosclerosis, vol.179, issue.1, pp.69-77, 2005.

A. M. Aslanian and I. F. Charo, Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis, Circulation, vol.114, issue.6, pp.583-90, 2006.

P. G. Yancey, In vivo modulation of HDL phospholipid has opposing effects on SR-BI-and ABCA1-mediated cholesterol efflux, J Lipid Res, vol.45, issue.2, pp.337-383, 2004.

B. Haidar, Cellular cholesterol efflux is modulated by phospholipid-derived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts, J Lipid Res, vol.42, issue.2, pp.249-57, 2001.

P. Marmillot, S. Patel, and M. R. Lakshman, Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins, Metabolism, vol.56, issue.2, pp.251-259, 2007.

T. Kimura, K. Sato, A. Kuwabara, H. Tomura, M. Ishiwara et al., Sphingosine 1-Phosphate May Be a Major Component of Plasma Lipoproteins Responsible for the Cytoprotective Actions in Human Umbilical Vein Endothelial Cells, Journal of Biological Chemistry, vol.276, issue.34, pp.31780-31785, 2001.

J. R. Nofer and G. Assmann, Atheroprotective Effects of High-Density Lipoprotein-Associated Lysosphingolipids, Trends in Cardiovascular Medicine, vol.15, issue.7, pp.265-271, 2005.

J. A. De-souza, C. Vindis, B. Hansel, A. Nègre-salvayre, P. Therond et al., Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity, Atherosclerosis, vol.197, issue.1, pp.84-94, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00408921

T. A. Taha, T. D. Mullen, and L. M. Obeid, A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death, Biochim Biophys Acta, vol.1758, issue.12, pp.2027-2063, 2006.

V. T. Dang, Comprehensive Plasma Metabolomic Analyses of Atherosclerotic Progression Reveal Alterations in Glycerophospholipid and Sphingolipid Metabolism in Apolipoprotein Edeficient Mice, vol.6, p.35037, 2016.

V. N. Bochkov, O. V. Oskolkova, K. G. Birukov, A. Levonen, C. J. Binder et al., Generation and Biological Activities of Oxidized Phospholipids, Antioxidants & Redox Signaling, vol.12, issue.8, pp.1009-1059, 2010.

E. Stachowska, A. Siennicka, M. Ba?kiewcz-ha?asa, J. Bober, B. Machalinski et al., Conjugated linoleic acid isomers may diminish human macrophages adhesion to endothelial surface, International Journal of Food Sciences and Nutrition, vol.63, issue.1, pp.30-35, 2011.

Y. Song, L. Zhang, H. Li, Y. Gu, F. Li et al., Polyunsaturated fatty acid relatively decreases cholesterol content in THP-1 macrophage-derived foam cell: partly correlates with expression profile of CIDE and PAT members, Lipids in Health and Disease, vol.12, issue.1, p.111, 2013.

M. Sato, K. Shibata, R. Nomura, D. Kawamoto, R. Nagamine et al., Linoleic acid-rich fats reduce atherosclerosis development beyond its oxidative and inflammatory stress-increasing effect in apolipoprotein E-deficient mice in comparison with saturated fatty acid-rich fats, British Journal of Nutrition, vol.94, issue.6, pp.896-901, 2005.

A. Lykidis, P. D. Jackson, C. O. Rock, and S. Jackowski, The Role of CDP-Diacylglycerol Synthetase and Phosphatidylinositol Synthase Activity Levels in the Regulation of Cellular Phosphatidylinositol Content, Journal of Biological Chemistry, vol.272, issue.52, pp.33402-33409, 1997.

L. Malinina, D. K. Simanshu, X. Zhai, V. R. Samygina, R. Kamlekar et al., Sphingolipid transfer proteins defined by the GLTP-fold, Quarterly Reviews of Biophysics, vol.48, issue.3, pp.281-322, 2015.

M. Kurano, K. Tsukamoto, S. Kamitsuji, N. Kamatani, M. Hara et al., Genome-wide association study of serum lipids confirms previously reported associations as well as new associations of common SNPs within PCSK7 gene with triglyceride, Journal of Human Genetics, vol.61, issue.5, pp.427-433, 2016.

E. Y. Lee, P. T. Klementowicz, R. A. Hegele, B. F. Asztalos, and E. J. Schaefer, HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature, Journal of Clinical Lipidology, vol.7, issue.2, pp.169-173, 2013.

N. Murayama, Y. Asano, K. Kato, Y. Sakamoto, S. Hosoda et al., Effects of plasma infusion on plasma lipids, apoproteins and plasma enzyme activities in familial lecithin: cholesterol acyltransferase deficiency, European Journal of Clinical Investigation, vol.14, issue.2, pp.122-129, 1984.

R. D. Shamburek, R. Bakker-arkema, B. J. Auerbach, B. R. Krause, R. Homan et al., Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement, Journal of Clinical Lipidology, vol.10, issue.2, pp.356-367, 2016.

A. Hafiane, B. Jabor, I. Ruel, J. Ling, and J. Genest, High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes, The American Journal of Cardiology, vol.113, issue.2, pp.249-255, 2014.

O. Quehenberger and E. A. Dennis, The Human Plasma Lipidome, New England Journal of Medicine, vol.365, issue.19, pp.1812-1823, 2011.

A. Bounafaa, H. Berrougui, S. Ikhlef, A. Essamadi, B. Nasser et al., Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients, Clinical Biochemistry, vol.47, issue.18, pp.318-325, 2014.

M. Riwanto, L. Rohrer, B. Roschitzki, C. Besler, P. Mocharla et al., Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease, Circulation, vol.127, issue.8, pp.891-904, 2013.

N. Lindbohm, H. Gylling, T. E. Miettinen, and T. A. Miettinen, Sialic acid content of LDL and lipoprotein metabolism in combined hyperlipidemia and primary moderate hypercholesterolemia, Clinica Chimica Acta, vol.285, issue.1-2, pp.69-84, 1999.

L. R. Ruhaak, C. Huhn, W. Waterreus, A. R. De-boer, C. Neusu?ss et al., Hydrophilic Interaction Chromatography-Based High-Throughput Sample Preparation Method for N-Glycan Analysis from Total Human Plasma Glycoproteins, Analytical Chemistry, vol.80, issue.15, pp.6119-6126, 2008.

T. Vaisar, Proteomics Investigations of HDL: Challenges and Promise, Current Vascular Pharmacology, vol.10, issue.4, pp.410-421, 2012.

M. Vauhkonen, J. Viitala, J. Parkkinen, and H. Rauvala, High-mannose structure of apolipoprotein-B from low-density lipoproteins of human plasma, European Journal of Biochemistry, vol.152, issue.1, pp.43-50, 1985.

A. Varki, Sialic acids in human health and disease, Trends in Molecular Medicine, vol.14, issue.8, pp.351-360, 2008.

R. Schauer, Sialic acids as regulators of molecular and cellular interactions, Current Opinion in Structural Biology, vol.19, issue.5, pp.507-514, 2009.

F. Lehmann, E. Tiralongo, and J. Tiralongo, Sialic acid-specific lectins: occurrence, specificity and function, Cellular and Molecular Life Sciences CMLS, vol.63, issue.12, pp.1331-1354, 2006.

P. H. Weigel and J. H. Yik, Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1572, issue.2-3, pp.341-363, 2002.

G. Lindberg, G. A. Eklund, B. Gullberg, and L. Rastam, Serum sialic acid concentration and cardiovascular mortality., BMJ, vol.302, issue.6769, pp.143-146, 1991.

H. Yokoyama, J. S. Jensen, T. Jensen, and T. Deckert, Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy, Journal of Internal Medicine, vol.237, issue.5, pp.519-523, 1995.

T. Keser, I. Gornik, F. Vu?kovi?, N. Selak, T. Pavi? et al., Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes, Diabetologia, vol.60, issue.12, pp.2352-2360, 2017.

M. C. Phillips, Molecular Mechanisms of Cellular Cholesterol Efflux, Journal of Biological Chemistry, vol.289, issue.35, pp.24020-24029, 2014.

M. Murakami, S. Horiuchi, K. Takata, and Y. Morino, Distinction in the Mode of Receptor-Mediated Endocytosis between High Density Lipoprotein and Acetylated High Density Lipoprotein: Evidence for High Density Lipoprotein Receptor-Mediated Cholesterol Transfer, Journal of Biochemistry, vol.101, issue.3, pp.729-741, 1987.

L. Ville and A. E. , In vitro oxidised HDL is recognised by the scavenger receptor of macrophages: implications for its protective role in vivo, Atherosclerosis, vol.105, issue.2, pp.179-189

J. G. Boucher, T. Nguyen, and D. L. Sparks, Lipoprotein electrostatic properties regulate hepatic lipase association and activity, Biochemistry and Cell Biology, vol.85, issue.6, pp.696-708, 2007.

J. Cubedo, T. Padró, and L. Badimon, Glycoproteome of human apolipoprotein A-I: N- and O-glycosylated forms are increased in patients with acute myocardial infarction, Translational Research, vol.164, issue.3, pp.209-222, 2014.

A. N. Orekhov, V. V. Tertov, S. N. Pokrovsky, . Adamova-iyu, O. N. Martsenyuk et al., Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination., Circulation Research, vol.62, issue.3, pp.421-429, 1988.

V. V. Tertov, A. N. Orekhov, O. N. Martsenyuk, N. V. Perova, and V. N. Smirnov, Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells, Experimental and Molecular Pathology, vol.50, issue.3, pp.337-347, 1989.

E. I. Chazov, A. N. Orekhov, N. V. Perova, K. A. Khashimov, V. V. Tertov et al., ATHEROGENICITY OF BLOOD SERUM FROM PATIENTS WITH CORONARY HEART DISEASE, The Lancet, vol.328, issue.8507, pp.595-598, 1986.

Y. Liu and D. Atkinson, Enhancing the Contrast of ApoB to Locate the Surface Components in the 3D Density Map of Human LDL, Journal of Molecular Biology, vol.405, issue.1, pp.274-283, 2011.

J. L. Sánchez-quesada, S. Villegas, and J. Ordóñez-llanos, Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding, Current Opinion in Lipidology, vol.23, issue.5, pp.479-486, 2012.

B. B. Boyanovsky, D. R. Van-der-westhuyzen, and N. R. Webb, Group V Secretory Phospholipase A2-modified Low Density Lipoprotein Promotes Foam Cell Formation by a SR-A- and CD36-independent Process That Involves Cellular Proteoglycans, Journal of Biological Chemistry, vol.280, issue.38, pp.32746-32752, 2005.

K. J. Moore and M. W. Freeman, Scavenger Receptors in Atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.26, issue.8, pp.1702-1711, 2006.

V. V. Tertov, I. A. Sobenin, V. V. Kaplun, and A. N. Orekhov, Antioxidant content in low density lipoprotein and lipoprotein oxidationin vivoandin vitro, Free Radical Research, vol.29, issue.2, pp.165-173, 1998.

K. Kowalska, E. Socha, and H. Milnerowicz, Review: The role of paraoxonase in cardiovascular diseases, Ann Clin Lab Sci, vol.45, issue.2, pp.226-259, 2015.